
Kanoko Matsuyama
Retail, Health&Science Reporter for Bloomberg News in Tokyo.
Articles
-
3 weeks ago |
japantimes.co.jp | Hideyuki Sano |Kanoko Matsuyama
Japanese conglomerates are scaling back their hundreds of listed subsidiaries, a structure that critics say is often a poor use of capital and raises potential conflicts of interest. The trend stems from mounting pressure on companies to cater to shareholders in response to activist campaigns, demands from the stock exchange and even hostile takeovers.
-
3 weeks ago |
news.bloombergtax.com | Hideyuki Sano |Kanoko Matsuyama
Japanese conglomerates are scaling back their hundreds of listed subsidiaries, a structure that critics say is often a poor use of capital and raises potential conflicts of interest. The trend stems from mounting pressure on companies to cater to shareholders in response to activist campaigns, demands from the stock exchange and even hostile takeovers.
-
3 weeks ago |
bloomberg.com | Hideyuki Sano |Kanoko Matsuyama
The Nippon Telegraph and Telephone Corp. outside Otemachi First Square, which houses the company's head office, in Tokyo, Japan. (Bloomberg) -- Japanese conglomerates are scaling back their hundreds of listed subsidiaries, a structure that critics say is often a poor use of capital and raises potential conflicts of interest. The trend stems from mounting pressure on companies to cater to shareholders in response to activist campaigns, demands from the stock exchange and even hostile takeovers.
-
3 weeks ago |
bloomberglinea.com | Alice French |Kanoko Matsuyama |Lisa Pham |Simon Dawson
Bloomberg — Las acciones de las empresas farmacéuticas cayeron en todo el mundo después de que el presidente de EE.UU., Donald Trump, anunciara su intención de ordenar una reducción de los costos de los medicamentos recetados en EE.UU. para equipararlos a los de otros países. Esto generó preocupación sobre el impacto en las ganancias del sector. Farmacéuticas europeas, entre ellas Novo Nordisk A/S (NVO), AstraZeneca Plc (AZN) y Roche Holding AG, se desplomaron.
-
3 weeks ago |
bloomberg.com | Alice French |Kanoko Matsuyama |Lisa Pham
Las acciones de las empresas farmacéuticas cayeron en todo el mundo después de que el presidente de EE.UU., Donald Trump, anunciara su intención de ordenar una reducción de los costos de los medicamentos recetados en EE.UU. para equipararlos a los de otros países. Esto generó preocupación sobre el impacto en las ganancias del sector. Farmacéuticas europeas, entre ellas Novo Nordisk A/S, AstraZeneca Plc y Roche Holding AG, se desplomaron.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 618
- Tweets
- 65
- DMs Open
- No

RT @natalieobiko: From the Sabew judges: an "extraordinary work of investigative journalism," "un-put-downable," and "the writing is equal…

RT @natalieobiko: Shout out to my incredible co-reporters @JessicaVBrice @susanberfield @VTSilver @kanokomatsuyama @nailakhan05 @advait_px,…

RT @natalieobiko: If reading isn't your thing (the story is long!), @bbgoriginals has produced a short film, Inside India’s Rush for Human…